BofA analyst Travis Steed lowered the firm’s price target on DexCom (DXCM) to $80 from $100 and keeps a Buy rating on the shares following the company’s analyst day and manufacturing tour. The firm updated its target for lower peer multiples and now uses 25-times its 2027 EPS estimate, versus 35-times previously, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: